HUTCHMED (China) Limited

18.77 USD
-0.01 (-0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

HUTCHMED (China) Limited stock is down -3.64% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 87.5% of the previous 7 November’s closed higher than October. 50% of analysts rate it a buy.

About HUTCHMED (China) Limited

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) In addition, it develops Tazemetostat, an inhibitors of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients.

  • Deutsche Bank
    Fri Nov 24, 04:59
  • Goldman Sachs
    Fri Nov 10, 11:03